Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole IM Depot PK and Safety in Schizophrenia (Deltoid Injection)
NCT02220712Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: OPC-14597 Plasma Concentration 672 Hours Postdose and Incidence of Treatment-Emergent Adverse Events up to 20 weeks. Started Jul 2014; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02220712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220712.